- Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin as Treatment for Major Depressive Disorder
November 4th, 2011 - Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds
October 12th, 2011 - Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin
October 3rd, 2011 - Rexahn Pharmaceuticals Completes Patient Enrollment for Archexin Phase II Clinical Trial in Metastatic Pancreatic Cancer
September 28th, 2011 - Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
September 8th, 2011 - Rexahn Pharmacueticals Announces US Patent Issued for CNS-based Treatment of Sexual Dysfunction
September 6th, 2011 - European Patent granted for Neurotherapeutic Compositions
August 22nd, 2011 - Rexahn Pharmaceuticals Completes Patient Enrollment in Serdaxin Phase IIb Clinical Trial for Major Depressive Disorder
June 22nd, 2011 - Rexahn Pharmaceuticals Reports Enrollment Progress on Phase IIb Clinical Trial of Serdaxin for Depression
May 5th, 2011 - Rexahn Pharmaceuticals to Present at Needham & Company’s 10th Annual Healthcare Conference
April 4th, 2011 - Rexahn Closes $10 Million in Registered Direct Offering
March 31st, 2011 - Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-5902 at AACR 102nd Annual Meeting
March 30th, 2011 - Rexahn to Raise $10 Million in Registered Direct Offering
March 28th, 2011 - Rexahn Pharmaceuticals Enrolls 100 Patients in Serdaxin Phase IIb Clinical Trial for Depression
March 23rd, 2011 - Rexahn Pharmaceuticals to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
March 14th, 2011 - Rexahn Announces CEO Transition to CSO and Search for New CEO
March 7th, 2011 - Rexahn Pharmaceuticals Granted European Patent for New Quinoxalinyl-piperazine Compounds
February 28th, 2011 - Rexahn Pharmaceuticals Enrolls First Patient in Serdaxin Phase IIb Clinical Trial
January 25th, 2011 - Teva Pharmaceutical Increases Its Investment in Rexahn For the Continued Research and Development of the Pre-clinical Anti-Cancer Compound, RX-3117
January 20th, 2011
2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003